Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma
Table 3
Baseline demographics and clinical characteristics of patients with advanced HBV-related HCC.
TLV ()
ETV ()
value
Age, years
55.8 ± 8.5
60.4 ± 6.3
0.149
Male
9
11
0.038
CP class, B/C
9 (64.2%)/5 (35.7%)
11/0
0.038
ALT, IU/L
94.5 ± 108.8
122.0 ± 267.6
0.728
Prothrombin time, INR
1.35 ± 0.25
1.3 ± 0.12
0.524
Albumin, g/dL
2.82 ± 0.44
3.00 ± 0.47
0.362
Total bilirubin, mg/dL
3.07 ± 2.45
1.95 ± 0.61
0.156
Platelet count, 103/mL
159.1 ± 90.9
95.4 ± 36.3
0.040
Median alpha fetoprotein, range, ng/mL
37707.1 (715902.5)
298.9 (27346)
0.053
HBV DNA concentration, log10 IU/mL
6.40 ± 0.71
5.45 ± 1.40
0.038
HBeAg positivity
9 (64.2%)
5 (45.6%)
0.296
Tumor stage TNM stages III/IVa/IVb
3/5/6
5/4/2
0.319
Mean observation time (days)
162.4 ± 160.5
265.9 ± 219.7
0.622
Death
9 (64.2%)
6 (54.5%)
0.466
Variables are expressed as means ± standard deviation (SD), medians (ranges), or (%). TLV, telbivudine; ETV, entecavir; CP, Child-Pugh; ALT, alanine transaminase; INR, international normalized ratio; HBeAg, hepatitis B e antigen; and TNM, tumor-node-metastasis.
